Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe

BACKGROUND: Many European countries introduced (confidential) rebates in the past years. Authorities and manufacturers argue that this strategy allows reduction of spending on high-cost drugs, and quick access of innovative drugs. We evaluated these arguments using Switzerland as an example, one of...

Descripción completa

Detalles Bibliográficos
Autores principales: Carl, David L, Vokinger, Kerstin N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610666/
https://www.ncbi.nlm.nih.gov/pubmed/33899044
http://dx.doi.org/10.1016/j.lanepe.2021.100050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610666/
https://www.ncbi.nlm.nih.gov/pubmed/33899044
http://dx.doi.org/10.1016/j.lanepe.2021.100050

Ejemplares similares